• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    4/26/23 1:31:17 PM ET
    $APLM
    $BXRX
    $CCEL
    $CTKB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $APLM alert in real time by email

    Gainers

    • EUDA Health Holdings (NASDAQ:EUDA) shares rose 45.3% to $2.14 during Wednesday's regular session. As of 13:30 EST, EUDA Health Holdings's stock is trading at a volume of 13.1 million, which is 1251.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $47.7 million.
    • Etao International Co (NASDAQ:ETAO) shares rose 34.66% to $1.01. Trading volume for this security as of 13:30 EST is 9.9 million, which is 1358.4% of its average full-day volume over the last 100 days. The company's market cap stands at $103.3 million.
    • Cryo-Cell International (AMEX:CCEL) stock rose 28.67% to $5.34. The market value of their outstanding shares is at $44.3 million. The company's, Q1 earnings came out 3 days ago.
    • Vaxxinity (NASDAQ:VAXX) shares rose 20.8% to $2.09. The current volume of 297.6K shares is 135.0% of Vaxxinity's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $263.4 million.
    • Cytek Biosciences (NASDAQ:CTKB) stock rose 14.62% to $10.97. The current volume of 1.8 million shares is 274.5% of Cytek Biosciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $1.4 billion.
    • Minerva Neurosciences (NASDAQ:NERV) shares moved upwards by 14.15% to $2.66. The market value of their outstanding shares is at $14.2 million.

    Losers

    • ZyVersa Therapeutics (NASDAQ:ZVSA) shares fell 70.6% to $0.47 during Wednesday's regular session. The current volume of 11.0 million shares is 2938.6% of ZyVersa Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $4.3 million.
    • Baudax Bio (NASDAQ:BXRX) stock decreased by 27.76% to $1.51. As of 13:30 EST, this security is trading at a volume of 1.8 million shares, making up 161.5% of its average full-day volume over the last 100 days. The company's market cap stands at $3.9 million.
    • Evelo Biosciences (NASDAQ:EVLO) shares decreased by 27.39% to $0.11. Trading volume for this security as of 13:30 EST is 1.9 million, which is 588.4% of its average full-day volume over the last 100 days. The company's market cap stands at $12.0 million.
    • Apollomics (NASDAQ:APLM) shares fell 26.36% to $4.75. Trading volume for this security as of 13:30 EST is 335.3K, which is 119.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $412.2 million.
    • GRI Bio (NASDAQ:GRI) stock decreased by 24.79% to $6.1. As of 13:30 EST, GRI Bio's stock is trading at a volume of 58.6K, which is 31.7% of its average full-day volume over the last 100 days.
    • TRACON Pharma (NASDAQ:TCON) stock fell 24.74% to $0.71. As of 13:30 EST, this security is trading at a volume of 1.0 million shares, making up 710.7% of its average full-day volume over the last 100 days. The company's market cap stands at $17.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APLM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM
    $BXRX
    $CCEL
    $CTKB

    CompanyDatePrice TargetRatingAnalyst
    Cytek Biosciences Inc.
    $CTKB
    12/2/2025$6.00Equal-Weight
    Morgan Stanley
    Cytek Biosciences Inc.
    $CTKB
    5/9/2025$4.00Buy → Hold
    TD Cowen
    Cytek Biosciences Inc.
    $CTKB
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Cytek Biosciences Inc.
    $CTKB
    12/14/2023$9.00Overweight
    Stephens
    Vaxxinity Inc.
    $VAXX
    9/8/2023$7.00Outperform
    Robert W. Baird
    Cytek Biosciences Inc.
    $CTKB
    7/19/2023Mkt Perform
    Raymond James
    Vaxxinity Inc.
    $VAXX
    4/27/2022In-line
    Evercore ISI
    More analyst ratings

    $APLM
    $BXRX
    $CCEL
    $CTKB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

    SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    3/26/26 5:40:11 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Minerva Neurosciences Inc

    EFFECT - Minerva Neurosciences, Inc. (0001598646) (Filer)

    3/20/26 12:15:13 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    3/19/26 4:15:25 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    $APLM
    $BXRX
    $CCEL
    $CTKB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

    Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25

    3/25/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EUDA Announces Reverse Stock Split of its Ordinary Shares

    SINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it will implement a reverse stock split of its ordinary shares at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split was approved by the Company's Board of Directors in accordance with British Virgin Islands law. The Reverse Stock Split will take effect at market open on March 23, 2026, and the ordinary shares will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol "EUDA" and will con

    3/19/26 5:30:00 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    Cryo-Cell Receives NYSE American Continued Listing Notice

    Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders' deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30,

    3/12/26 5:00:00 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    $APLM
    $BXRX
    $CCEL
    $CTKB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Chen Hung-Wen

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/19/26 2:02:48 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chen Hong-Jung

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/18/26 6:52:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chu Yi-An

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/18/26 6:46:11 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $BXRX
    $CCEL
    $CTKB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Co-CEO Portnoy David bought $76,486 worth of shares (17,175 units at $4.45), increasing direct ownership by 2% to 827,344 units (SEC Form 4)

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    9/18/25 4:53:49 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Chairman, Co-CEO Portnoy David bought $189,986 worth of shares (42,900 units at $4.43), increasing direct ownership by 0.89% to 811,920 units (SEC Form 4)

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    9/10/25 5:22:01 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Chairman, Co-CEO Portnoy David bought $176,198 worth of shares (39,179 units at $4.50) (SEC Form 4)

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    8/27/25 5:23:37 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    $APLM
    $BXRX
    $CCEL
    $CTKB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Cytek Biosciences with a new price target

    Morgan Stanley resumed coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $6.00

    12/2/25 8:24:49 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences downgraded by TD Cowen with a new price target

    TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

    5/9/25 8:41:00 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences downgraded by Goldman with a new price target

    Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

    1/31/25 6:59:30 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $APLM
    $BXRX
    $CCEL
    $CTKB
    Leadership Updates

    Live Leadership Updates

    View All

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

    IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

    7/3/25 1:00:00 PM ET
    $CTKB
    $MDXH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $APLM
    $BXRX
    $CCEL
    $CTKB
    Financials

    Live finance-specific insights

    View All

    Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

    Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024. Net (Loss) Income The Company repo

    2/27/26 5:00:00 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

    FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of

    2/26/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the n

    2/12/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $APLM
    $BXRX
    $CCEL
    $CTKB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    11/14/24 6:01:27 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 4:35:51 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials